1. Home
  2. TDOC vs MESO Comparison

TDOC vs MESO Comparison

Compare TDOC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TDOC
  • MESO
  • Stock Information
  • Founded
  • TDOC 2002
  • MESO 2004
  • Country
  • TDOC United States
  • MESO Australia
  • Employees
  • TDOC N/A
  • MESO N/A
  • Industry
  • TDOC Medical/Nursing Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TDOC Health Care
  • MESO Health Care
  • Exchange
  • TDOC Nasdaq
  • MESO Nasdaq
  • Market Cap
  • TDOC 1.5B
  • MESO 1.3B
  • IPO Year
  • TDOC 2015
  • MESO N/A
  • Fundamental
  • Price
  • TDOC $8.58
  • MESO $16.09
  • Analyst Decision
  • TDOC Buy
  • MESO Buy
  • Analyst Count
  • TDOC 19
  • MESO 4
  • Target Price
  • TDOC $9.65
  • MESO $18.00
  • AVG Volume (30 Days)
  • TDOC 7.6M
  • MESO 309.2K
  • Earning Date
  • TDOC 07-29-2025
  • MESO 08-28-2025
  • Dividend Yield
  • TDOC N/A
  • MESO N/A
  • EPS Growth
  • TDOC N/A
  • MESO N/A
  • EPS
  • TDOC N/A
  • MESO N/A
  • Revenue
  • TDOC $2,552,812,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • TDOC N/A
  • MESO $178.09
  • Revenue Next Year
  • TDOC $1.36
  • MESO $305.06
  • P/E Ratio
  • TDOC N/A
  • MESO N/A
  • Revenue Growth
  • TDOC N/A
  • MESO N/A
  • 52 Week Low
  • TDOC $6.35
  • MESO $5.78
  • 52 Week High
  • TDOC $15.21
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • TDOC 59.77
  • MESO 73.44
  • Support Level
  • TDOC $7.83
  • MESO $14.45
  • Resistance Level
  • TDOC $8.81
  • MESO $16.07
  • Average True Range (ATR)
  • TDOC 0.40
  • MESO 0.50
  • MACD
  • TDOC -0.02
  • MESO 0.58
  • Stochastic Oscillator
  • TDOC 62.77
  • MESO 97.63

About TDOC Teladoc Health Inc.

Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with improved convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: